{"id":644782,"date":"2026-08-19T04:00:23","date_gmt":"2026-08-19T04:00:23","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/644782\/"},"modified":"2026-08-19T04:00:23","modified_gmt":"2026-08-19T04:00:23","slug":"what-the-bodys-early-warning-system-is-really-telling-us","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/644782\/","title":{"rendered":"What the body\u2019s early warning system is really telling us"},"content":{"rendered":"

New biomarkers promise early disease detection, but doctors using them daily struggle to weigh the value of these warnings.<\/strong> <\/p>\n

There\u2019s a kind of frustration that drives people out of conventional medicine and into prevention. For Dr Alexandru Ardelean, a specialist in internal medicine at Years<\/a>, it was a pattern, rather than a single moment. Working in the ER, he kept seeing the same cardiology patients cycle back through, and he started asking a question that traditional medicine isn\u2019t built to answer: when did this actually start?<\/p>\n

That question is the thread running through this week\u2019s episode of Longevity Technology UNLOCKED<\/a>, where hosts Dr Nina Patrick and Longevity.Technology CEO Phil Newman sit down with Ardelean and J\u00fcrgen Mehrtens, the clinician and CEO, respectively, behind Years, a Berlin-based longevity clinic betting its entire model on one idea: that the body sends out distress signals long before disease shows up on a chart.<\/p>\n

Two signals, in particular, are getting a lot of attention right now: GDF-15 and P-tau217. Neither is a household name yet. Both might be soon.<\/p>\n

Think of GDF-15 less as a diagnosis and more as your body\u2019s smoke detector; it doesn\u2019t tell you what\u2019s burning, only that something is. Ardelean describes it as a marker of generalized cellular stress, produced across a huge range of tissues in response to everything from mitochondrial dysfunction to chronic inflammation. It\u2019s already used clinically to help predict heart failure outcomes and, notably, in oncology, where it\u2019s linked to the appetite loss seen in cancer cachexia \u2013 one reason a pharmaceutical company has developed an antibody specifically targeting it.<\/p>\n

But its pull into longevity medicine came from a different body of research: studies showing GDF-15 tracks closely with chronological age, and that its trend over time, not a single snapshot, predicts mortality and illness down the line.<\/p>\n

As Ardelean put it: \u201cwe do not use these biomarkers as of yet in preventative medicine to build the therapeutic strategy. We use them in order to measure the therapeutic success,\u201d meaning a high reading doesn\u2019t hand you a treatment plan. It tells you whether the plan you\u2019re already on is working.<\/p>\n

What made this conversation refreshing is that it didn\u2019t oversell the science. Pressed on whether these markers throw off false positives, Ardelean\u2019s answer wasn\u2019t reassuring in the way marketing usually is; it was more useful than that.<\/p>\n

\u201cMy concern is not necessarily about false positives, it\u2019s about false negatives,\u201d he said, describing patients whose P-tau217, a marker tied to early Alzheimer\u2019s risk, came back elevated but who showed no cognitive symptoms, no genetic risk and scored well on testing. In those cases, the clinic leans on repeated measurement over time rather than reacting to one number.<\/p>\n

There\u2019s no settled reference range for GDF-15 in preventive use either; it can swing from 300 to 600 in a perfectly healthy 40-year-old. Ardelean even floated a working theory mid-interview, coining the idea of a \u201ccellular stress reserve,\u201d the notion that some people\u2019s healthy habits may be buying them a buffer that keeps the number looking normal even as underlying strain builds. It\u2019s a hypothesis, not a finding, and he said as much. That kind of transparency is rare, and it\u2019s worth more to patients than false certainty.<\/p>\n

The business model behind Years is arguably the more provocative part of this story. Mehrtens set out to build a longitudinal dataset, and realized the only way to guarantee data quality was to own the clinics generating it. Every client runs through an identical diagnostic protocol, repeated annually, no menu nor shortcuts. The pitch to future partners, including pharmaceutical companies, is a dataset clean enough to accelerate drug development.<\/p>\n

It\u2019s a bet that consistency beats convenience and a quiet rebuke of a healthcare system Mehrtens doesn\u2019t hesitate to criticize.<\/p>\n

\u201cOur healthcare system is broken,\u201d he said flatly, adding that it\u2019s likely true across most Western countries, Germany and the UK included.<\/p>\n

What stood out beyond the biomarkers was how much of Years\u2019 actual retention strategy is built on community \u2013 running clubs, book readings, patients sharing their own turnaround stories with each other. It\u2019s an implicit acknowledgment that data alone doesn\u2019t change behavior; belonging might. As competitors in the functional medicine space struggle with client retention because, in Mehrtens\u2019 words, patients often \u201cdon\u2019t see or feel a difference,\u201d Years is betting that visible, trackable progress \u2013 paired with people cheering each other on \u2013 is what keeps someone coming back for their next blood draw.<\/p>\n

Predictive biomarkers won\u2019t replace the boring fundamentals \u2013 sleep, movement, nutrition \u2013 anytime soon. But they might finally give people a reason to take them seriously before the ER visit, not after.<\/p>\n

Want to stay ahead of what\u2019s next in longevity? New episodes of Longevity.Technology UNLOCKED<\/a> land every Monday, followed by our weekly news roundup each Friday. Find us on \u00a0Apple Podcasts<\/a>,\u00a0Spotify<\/a><\/strong>\u00a0and\u00a0YouTube<\/a>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"New biomarkers promise early disease detection, but doctors using them daily struggle to weigh the value of these…\n","protected":false},"author":2,"featured_media":644783,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[275],"tags":[22664,20801,37516,18,135,475,474,19,17,146474,25569,2058],"class_list":["post-644782","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-biomarkers","tag-disease-detection","tag-early-detection","tag-eire","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-longevity-technology-unlocked","tag-podcast","tag-years"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117120180440179597","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/644782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=644782"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/644782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/644783"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=644782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=644782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=644782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}